Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fluent, Inc.COGT · Entity 6736 | Director | April 13, 2017 | April 17, 2017 |
| Niagen Bioscience, Inc.NAGE · Entity 6146 | Director · Chief Executive Officer | June 30, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fluent, Inc.
Report date April 13, 2017 · Filed April 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2017-04-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-04-13 · Grant · Acquired 15,000 · Balance 15,000 F1: On April 13, 2017, the reporting person received a grant of 15,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions. F2: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date. |
| Common StockSEC Table I · non-derivative | Direct | 360,672 |
Reported balance
Holding disclosure · report date 2017-04-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 360,672 |
| Common StockSEC Table I · non-derivative | Direct | 13,333 |
Reported balance
Holding disclosure · report date 2017-04-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 13,333 F3: On November 16, 2015, the reporting person received a grant, subject to stockholder approval which was obtained June 1, 2016, of 20,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three equal annual installments beginning November 16, 2016 (the "Time Conditions") provided, however, that no tranche of RSUs will vest until it is determined that Cogint, Inc. has exceeded certain revenue targets and achieved positive EBITDA in any one fiscal year during the vesting period (the "Performance Conditions"). Cogint, Inc. determined the Performance Conditions were met effective March 14, 2017. As such, the subsequent tranches vest equally on November 16, 2017 and November 16, 2018. F4: The RSUs will immediately vest upon (i) a Change of Control, or (ii) the reporting person's death or disability. |
| Common StockSEC Table I · non-derivative | Direct | 16,666 |
Reported balance
Holding disclosure · report date 2017-04-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 16,666 F5: Represents RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest on March 21, 2018, subject to accelerated vesting under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 13, 2017, the reporting person received a grant of 15,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions.
F2: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date.
F3: On November 16, 2015, the reporting person received a grant, subject to stockholder approval which was obtained June 1, 2016, of 20,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three equal annual installments beginning November 16, 2016 (the "Time Conditions") provided, however, that no tranche of RSUs will vest until it is determined that Cogint, Inc. has exceeded certain revenue targets and achieved positive EBITDA in any one fiscal year during the vesting period (the "Performance Conditions"). Cogint, Inc. determined the Performance Conditions were met effective March 14, 2017. As such, the subsequent tranches vest equally on November 16, 2017 and November 16, 2018.
F4: The RSUs will immediately vest upon (i) a Change of Control, or (ii) the reporting person's death or disability.
F5: Represents RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest on March 21, 2018, subject to accelerated vesting under certain conditions.
Niagen Bioscience, Inc.
Report date June 30, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,060,087 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,106 · Balance 1,060,087 F1: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d). |
| Common StockSEC Table I · non-derivative | IndirectBy Fried-Travis Revocable Trust U/A Dated 06/02/1999 | 95,001 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 95,001 |
| Common StockSEC Table I · non-derivative | IndirectBy US Trust Co. of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020 | 250,000 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 250,000 F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy US Trust Co. of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020 | 250,000 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 250,000 F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,746 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 12,746 F3: 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 8, 2026 21:16 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantCommon Stock | 1,106 | $2.71 | $2,997.26 |
DisclosureSEC source: 0001417952-26-000002 · wk-form4_1783545408.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060,087 F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 12:33 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001417952-26-000001 · wk-form4_1777293236.xml · derivative · entry 6 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 12:33 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | Exercise / conversionCommon Stock | 20,000 | $2.61 | $52,200.00 |
DisclosureSEC source: 0001417952-26-000001 · wk-form4_1777293236.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,058,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 21:44 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 503,937 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0001628280-26-011159 · wk-form4_1771969496.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,937 Underlying: Common Stock · 503,937 shares Expires 2036-02-18 F1 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on each anniversary of the grant date. Read SEC document |
| April 09, 2025 Filed Apr 9, 2025 23:52 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | Exercise / conversionStock Options (right to buy) · Derivative | 66,667 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001628280-25-017223 · wk-form4_1744242755.xml · derivative · entry 6 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,667 shares Expires 2025-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2025 Filed Apr 9, 2025 23:52 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | Exercise / conversionCommon Stock | 66,667 | $3.30 | $220,001.10 |
DisclosureSEC source: 0001628280-25-017223 · wk-form4_1744242755.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on July 29, 2025, paying the exercise price with cash, and has not sold any of the shares received upon exercise. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 21:42 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantPerformance Stock Unit · Derivative | 1,518,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008721 · wk-form4_1740692548.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,518,600 Underlying: Common Stock · 1,518,600 shares Expires 2032-02-25 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the company's common stock when vested. The PSUs vest incrementally upon the Company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and subject to a change in control. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the company's common stock when vested. The PSUs vest incrementally upon the Company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and subject to a change in control. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:17 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 492,278 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001628280-25-005851 · wk-form4_1739575019.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,278 Underlying: Common Stock · 492,278 shares Expires 2035-02-11 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 12, 2026 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 01:59 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 399,568 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001628280-24-006724 · wk-form4_1708739974.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,568 Underlying: Common Stock · 399,568 shares Expires 2034-02-21 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:27 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 7,000 | $1.42 | $9,940.00 |
DisclosureSEC source: 0001628280-23-020508 · wk-form4_1685651259.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Fried-Travis Revocable Trust U/A Dated 06/02/1999 Disclosed balance after: 95,001 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:05 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 306,366 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001628280-23-004086 · wf-form4_167667149838499.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Cheif Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,366 Underlying: Common Stock · 306,366 shares Expires 2033-02-14 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 15, 2024 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 00:17 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 80,000 | $1.25 | $100,000.00 |
DisclosureSEC source: 0001628280-22-025915 · wf-form4_166484261652383.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · Cheif Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,314 Read SEC document |
| March 16, 2022 Filed Mar 16, 2022 23:28 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 25,000 | $2.16 | $54,000.00 |
DisclosureSEC source: 0001628280-22-006443 · wf-form4_164747330857843.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fried-Travis Revocable Trust U/A Dated 06/02/1999 Disclosed balance after: 88,001 F1 · price: The weighted average purchase price for the transaction reported was $2.16, and the range of prices were between $2.14 and $2.16, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:28 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 240,448 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001628280-22-003371 · wf-form4_164556891215777.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,448 Underlying: Common Stock · 240,448 shares Expires 2032-02-16 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| May 13, 2021 Filed May 17, 2021 12:30 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 10,000 | $6.65 | $66,500.00 |
DisclosureSEC source: 0001415889-21-002499 · form4-05172021_080502.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fried-Travis Revocable Trust U/A Dated 06/02/1999 Disclosed balance after: 63,001 F1 · price: The weighted average purchase price for the transaction reported was $6.65, and the range of prices were between $6.64 and $6.66. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:43 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 55,921 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001415889-21-001547 · form4-03172021_030338.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,921 Underlying: Common Stock · 55,921 shares Expires 2031-03-14 F1 · derivative.exercise_date: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month. Read SEC document |
| May 19, 2020 Filed May 19, 2020 20:34 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 1,000 | $4.69 | $4,690.00 |
DisclosureSEC source: 0001415889-20-001263 · form4-05192020_010544.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,393,314 Read SEC document |
| April 17, 2020 Filed Apr 1, 2021 23:24 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GiftCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001778 · form4-04012021_040432.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,561 F1 · kind: On April 17, 2020, the Reporting Person transferred an aggregate of 500,000 shares to trusts established for the benefit of his children as follows: 250,000 shares to US Trust Company of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020 and 250,000 shares to US Trust Company of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020. F2 · balance_after: 1,000 shares held by the Reporting Person were inadvertently reported on a prior Form 4 filing as held directly. Instead, the shares are held by the Reporting Person indirectly in the name of the Fried-Travis Revocable Trust U/A Dated 06/02/1999. F3 · balance_after: 9,753 shares held by the Reporting Person were inadvertently reported on prior Form 4 filings as held directly. Instead, the shares are held by the Reporting Person indirectly in the name of Fried Films Profit Sharing. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 01:23 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 165,155 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001415889-20-000544 · form4-02272020_050218.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,155 Underlying: Common Stock · 165,155 shares Expires 2030-02-25 F1 · derivative.exercise_date: Options vest 33% on February 25, 2021 and thereafter 1/36th vest each month. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 15:49 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 10,000 | $3.09 | $30,900.00 |
DisclosureSEC source: 0001415889-19-001311 · form4-11152019_071126.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444,315 F1 · balance_after: Previous Form 4's disclosing the Reporting Person's beneficial ownership inadvertently overstated the number of shares directly beneficially owned by the Reporting Person by 2,012 shares. The number of shares is corrected in this Form 4. Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 12:00 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 2,500 | $4.03 | $10,075.00 |
DisclosureSEC source: 0001415889-19-000953 · form4-08262019_080802.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,436,327 Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:38 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 2,253 | $4.43 | $9,980.79 |
DisclosureSEC source: 0001415889-19-000563 · form4-05222019_010552.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,827 Read SEC document |
| March 15, 2019 Filed Mar 16, 2019 00:14 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,000 | $3.80 | $19,000.00 |
DisclosureSEC source: 0001415889-19-000338 · form4-03152019_050350.xml · nonDerivative · entry 2 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,431,574 Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:14 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 166,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000338 · form4-03152019_050350.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426,574 F1 · shares: These fully-vested shares are awarded to Mr. Fried pursuant to the achievement of the performance criteria detailed in his Executive Employment Agreement, dated March 12, 2017, as amended. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:37 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 162,569 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001415889-19-000221 · form4-02222019_040253.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,569 Underlying: Common Stock · 162,569 shares Expires 2029-02-21 F1 · derivative.exercise_date: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month. Read SEC document |
| February 15, 2019 Filed Feb 14, 2020 21:10 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GiftCommon Stock | 52,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000337 · form5-02142020_010232.xml · nonDerivative · entry 2 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fried-Travis Revocable Trust U/A Dated 06/02/1999 Disclosed balance after: 52,001 Read SEC document |
| February 15, 2019 Filed Feb 14, 2020 21:10 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GiftCommon Stock | 52,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000337 · form5-02142020_010232.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,392,314 Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 22:18 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 166,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001610 · form4-11092018_021156.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259,908 F1 · shares: These fully-vested shares are awarded to Mr. Fried pursuant to the achievement of the performance criteria detailed in his Executive Employment Agreement, dated March 12, 2017, as amended. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:17 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 744,097 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001415889-18-001033 · form4-06262018_020606.xml · derivative · entry 3 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,097 Underlying: Common Stock · 744,097 shares Expires 2028-06-22 F3 · shares: Awarded pursuant to his Amended and Restated Executive Employment Agreement dated June 22, 2018, in consideration of his appointment by the Board to CEO. F4 · derivative.exercise_date: 1/3rd of the shares vest on June 22, 2019 and the remaining shares vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:17 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 166,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001033 · form4-06262018_020606.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093,241 F1 · shares: These fully-vested shares are awarded to Mr. Fried pursuant to the achievement of the performance criteria detailed in his Executive Employment Agreement, dated March 12, 2017, as amended. Read SEC document |
| May 15, 2018 Filed May 15, 2018 21:34 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 10,000 | $3.63 | $36,300.00 |
DisclosureSEC source: 0001415889-18-000738 · form4-05152018_020536.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,574 Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:10 UTC Amendment | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 10,000 | $3.63 | $36,300.00 |
DisclosureSEC source: 0001415889-18-000742 · form4a-05162018_090510.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,574 F1 · kind: This Form 4 is being amended to correct the transaction code to reflect that the shares were purchased by the Reporting Person on the open market. Read SEC document |
| January 21, 2018 Filed Jan 23, 2018 21:19 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 300,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0001415889-18-000106 · form4-01232018_010141.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-01-21 F1 · derivative.exercise_date: 10/36th of the shares vested on January 21, 2018 and thereafter 1/36th vest on the 12th of each month for the next 26 months. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:46 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-17-001978 · form4-12212017_021233.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, CHIEF STRATEGY OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,574 F1 · shares: On December 20, 2017, ChromaDex Corporation (the "Company") and Robert Fried entered into an amendment (the "Amendment") to Mr. Fried's existing Executive Employment Agreement, dated March 12, 2017. In connection with the Amendment, the Company granted to Mr. Fried 333,333 shares of restricted Common Stock pursuant to the Company's 2017 Equity Incentive Plan, which shares are fully-vested. F2 · balance_after: Includes 166,667 shares of restricted Common Stock previously granted by the Company on March 12, 2017. In connection with the Amendment, the Company accelerated in full the vesting of the 166,667 shares of restricted Common Stock previously granted to Mr. Fried on March 12, 2017. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 20:50 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 10,000 | $3.15 | $31,500.00 |
DisclosureSEC source: 0001415889-17-001399 · form4-08162017_010858.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, CHIEF STRATEGY OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,241 Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 20:46 UTC | Fluent, Inc. COGT · Entity 6736 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027064 · doc4.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: On April 13, 2017, the reporting person received a grant of 15,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions. F2 · security: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date. F1 · price: On April 13, 2017, the reporting person received a grant of 15,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions. F1 · balance_after: On April 13, 2017, the reporting person received a grant of 15,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions. Read SEC document |
| March 12, 2017 Filed Mar 14, 2017 21:26 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001415889-17-000415 · form4-03142017_020307.xml · derivative · entry 4 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, CHIEF STRATEGY OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-03-12 F4 · kind: The options were awarded pursuant to his employment with the issuer as President and Chief Strategy Officer. F5 · derivative.exercise_date: Options vest in equal monthly installments over three years. Read SEC document |
| March 12, 2017 Filed Mar 14, 2017 21:26 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 166,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-17-000415 · form4-03142017_020307.xml · nonDerivative · entry 2 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, CHIEF STRATEGY OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,241 F2 · shares: These are shares of restricted stock and were awarded pursuant to his employment with the issuer as President and Chief Strategy Officer. 1/3rd will vest on March 12, 2018, 1/3rd will vest on March 12, 2019 and 1/3rd will vest on March 12, 2020. Read SEC document |
| March 12, 2017 Filed Mar 14, 2017 21:26 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantCommon Stock | 339,595 | $2.72 | $923,698.40 |
DisclosureSEC source: 0001415889-17-000415 · form4-03142017_020307.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director · PRESIDENT, CHIEF STRATEGY OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,574 F1 · price: Received in exchange for the membership interests of Healthspan Research, LLC ("Healthspan") previously owned by the Reporting Person, valued at $923,697.41, in connection with the acquisition of the outstanding membership interests of Healthspan by ChromaDex Corporation (the "Company") (the "Acquisition"). The number of shares received by the Reporting Person was calculated using the closing bid price per share of the Company's common stock on the NASDAQ Capital Market on the last trading day before the effective date of the Acquisition, rounded up to the nearest share. The closing bid price of the Company's common stock on March 10, 2017, rounded up to the nearest share, was $2.72 per share. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:42 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001415889-16-007480 · form4-11182016_011138.xml · derivative · entry 1 Fried Robert N · CIK 0001417952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-11-16 F1 · derivative.exercise_date: Options vest 100% on November 16, 2017. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 12:53 UTC | Fluent, Inc. COGT · Entity 6736 | PurchaseCommon Stock | 2,000 | $3.75 | $7,500.00 |
DisclosureSEC source: 0001209191-16-148772 · doc4.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,338 Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:17 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 15,000 | $3.39 | $50,850.00 |
DisclosureSEC source: 0001415889-16-007054 · form4-09062016_010946.xml · nonDerivative · entry 1 Fried Robert N · CIK 0001417952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,979 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.